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ReovirusThe interferon-β (IFN-β) response is critical for protection against viral myocarditis in several mouse models,
and IFN-α or -β treatment is beneﬁcial against human viral myocarditis. The IFN-β response in cardiac
myocytes and cardiac ﬁbroblasts forms an integrated network for organ protection; however, the different
IFN-α subtypes have not been studied in cardiac cells. We developed a quantitative RT-PCR assay that
distinguishes between 13 highly conserved IFN-α subtypes and found that reovirus T3D induces ﬁve IFN-α
subtypes in primary cardiac myocyte and ﬁbroblast cultures: IFN-α1, -α2, -α4, -α5, and -α8/6. Murine IFN-
α1, -α2, -α4, or -α5 treatment induced IRF7 and ISG56 and inhibited reovirus T3D replication in both cell
types. This ﬁrst investigation of IFN-α subtypes in cardiac cells for any virus demonstrates that IFN-α is
induced in cardiac cells, that it is both subtype and cell type speciﬁc, and that it is likely important in the
antiviral cardiac response.
© 2009 Elsevier Inc. All rights reserved.Introduction
Many viruses infect the heart and N5% of the human population
has experienced some form of viral myocarditis (Esfandiarei and
McManus, 2008; Woodruff, 1980). Moreover, N50% of sudden deaths
in young adults are due to cardiac causes with N10% of those due to
myocarditis (Doolan et al., 2004; Puranik et al., 2005). Unfortunately,
cardiac myocytes are not readily replenished, with a recent report
suggesting only 1% cell renewal in the average human lifetime
(Bergmann et al., 2009). This cardiac vulnerability likely necessitates a
uniquely effective cardiac response to limit virus spread through the
heart until immune defenses can be deployed. The cytokine IFN-β
could provide this critical ﬁrst line of defense (Muller et al., 1994), and
indeed we have shown that IFN-β is a determinant of protection
against reovirus-induced myocarditis in a mouse model (Sherry et al.,
1998). That is, differences in the capacity of reovirus strains to induce
myocarditis correlate with differences in viral induction of IFN-β and
viral sensitivity to the antiviral effects of IFN-α/β in primary cultures
of cardiac myocytes. In addition, a non-myocarditic reovirus induces
cardiac lesions in mice lacking IFN-α/β function (Sherry et al., 1998).
Reovirus-induced myocarditis reﬂects direct viral cytopathogenic
effect in cardiac cells (Baty and Sherry, 1993), while coxsackievirus B
(CVB)-induced myocarditis reﬂects both direct and immune-mediat-
ed pathology (Huber, 2008; Whitton, 2002), and murine cytomega-iomedical Sciences, College of
Raleigh, NC 27606, USA. Fax:
).
ll rights reserved.lovirus-induced myocarditis (MCMV) likely reﬂects predominantly
immune-mediated damage (Lenzo et al., 2003). IFN-α/β provides
protection against myocarditis induced by CVB (Wang et al., 2007)
and MCMV (Bartlett et al., 2004; Cull et al., 2002) as well, suggesting
that regardless of mechanism, the IFN response plays an important
antiviral role. Importantly, IFN-β treatment clears virus from the heart
and improves cardiac function in patients with persistent viral
myocarditis (Kuhl et al., 2003, 2006).
IFN-β is expressed and secreted by most cell types in response to
viral infection or other stimuli (Kawai and Akira, 2008). Binding to the
IFN-α/β-receptor (IFNAR) stimulates a signal transduction cascade to
induce hundreds of interferon-stimulated genes (ISGs) (Khabar et al.,
2004), some of which have antiviral function (Sadler and Williams,
2008), and one of which is a transcription factor (IRF7) which can
further induce IFN-β and IFN-α4 in a positive ampliﬁcation loop
(Honda et al., 2005; Marie et al., 1998; Sato et al., 1998). However, this
signaling cascade is clearly cell type speciﬁc (Dafﬁs et al., 2008; van
Boxel-Dezaire et al., 2006). Previously, we found that cardiac
myocytes and cardiac ﬁbroblasts differ in their basal expression of
components in the IFN pathway, resulting in differences in their IFN-β
response to viral infection (Stewart et al., 2005; Zurney et al., 2007).
Our results suggested that high basal IFN-β expression in cardiac
myocytes pre-arms this vulnerable, non-replenishable cell type, while
high basal expression of latent components in the IFN response path
in adjacent cardiac ﬁbroblasts renders these cells more responsive to
IFN and prevents them from inadvertently serving as a reservoir for
viral replication and spread to cardiac myocytes. These studies
provided the ﬁrst indication of an integrated network of cell-type-
speciﬁc innate immune components for organ protection, and
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types relevant to the disease of interest.
Both IFN-α and IFN-β bind the IFN-α/β-receptor but with
different afﬁnities, resulting in induction of an overlapping but
distinct set of ISGs (Jaks et al., 2007). While IFN-β is expressed by
most cell types in response to viral infection or other stimuli, dendritic
cells are likely the predominant cells expressing IFN-α as an early step
in maturation of the adaptive immune response (Steinman and
Hemmi, 2006). Nonetheless, IFN-α expression has been detected in
many cell types, suggesting that direct protection against pathogens is
also an important function for IFN-α. Indeed, IFN-α is a component of
the most effective antiviral regimen currently available for treatment
of hepatitis C virus infection, and IFN-α has also been beneﬁcial to
patients with viral myocarditis (Daliento et al., 2003; Miric et al.,
1996; Stille-Siegener et al., 1995). Given that IFN-α and IFN-β bind the
same cell receptor and given the importance of both IFN-α and IFN-β
in protection against viral myocarditis, we wished to investigate IFN-
α expression and function in primary cultures of murine cardiac cells.
IFN-α is expressed inmany if not all mammalian species (Woelk et
al., 2007). While IFN-β is encoded by a single gene, mouse IFN-α is
encoded by at least 13 functional genes which share N80% DNA and
protein similarity (Hardy et al., 2004; van Pesch et al., 2004). This has
limited the reagents and technologies available for discernment of
individual IFN-α subtypes to determine their roles in protection
against pathogens. To differentiate between 13 highly conserved
murine IFN-α subtypes, we developed a 3′-base mismatch approach
to design primer pairs speciﬁc for each IFN-α subtype in quantitative
RT-PCR. We used this novel assay and puriﬁed preparations of
individual IFN-α subtypes to investigate IFN-α subtype expression
and function in cardiac myocytes and ﬁbroblasts. This ﬁrst investiga-
tion of viral induction of IFN-α in cardiac cells for any virus
demonstrates that IFN-α is induced in cardiac cells, that it is bothTable 1
Primers for subtype-speciﬁc detection of IFN-αa.
IFN-α subtypeb Accession no.c
IFN-α1 BALB/c X01974 Forward
Reverse
IFN-α1 129/Sv NM_010502 Forward
Reverse
IFN-α2 BALB/c X01969 Forward
Reverse
IFN-α4 BALB/c X01973 Forward
Reverse
IFN-α5 BALB/c X01971 Forward
Reverse
IFN-α6T 129/Sv AY220465 Forward
Reverse
IFN-α7 C57BL/6 AY225952 Forward
Reverse
IFN-α7/10 Swiss M13710 Forward
Reverse
IFN-α8/6 C57BL/6 AY225953 Forward
Reverse
IFN-α8/6 BALB/c X01972 Forward
Reverse
IFN-α9 BALB/c M13660 Forward
Reverse
IFN-α11 Swiss M68944 Forward
Reverse
IFN-α12 C57BL/6 NM_177361 Forward
Reverse
IFN-α13 C57BL/6 AY190047 Forward
Reverse
IFN-α14 129/Sv AY220462 Forward
Reverse
a Genomic DNA from Cr:NIH(S) mice was subjected to qRT-PCR using the indicated prime
product.
b Mouse strains used for sequence information are as indicated.
c Many sequences/accession numbers are as originally suggested in van Pesch et al., 200subtype and cell type speciﬁc, and that it is likely important in the
antiviral cardiac response.
Results
Design of qRT-PCR primer pairs and conﬁrmation of IFN-α
subtype speciﬁcity
To differentiate between 13 highly conserved IFN-α subtypes, a 3′-
base mismatch approach was adopted to design qRT-PCR primer
pairs. This method is based on the extreme speciﬁcity of the 3′
terminal nucleotide for primer extension, i.e., cDNA synthesis can be
extended only when its 3′ terminal nucleotide is complementary to
the template nucleotide. Since IFN-α gene sequences for Cr:NIH(S)
mice are unavailable, 15 primer pairs were designed using alternative
mouse sequences from GenBank, and then Cr:NIH(S) mouse genomic
DNA was used in qPCR to conﬁrm that the primer pairs could amplify
products from this heterologous mouse strain (Table 1). Each primer
pair generated a single peak in a standard melt–curve analysis (data
not shown), indicating ampliﬁcation of a single product. Next, total
cell RNA was harvested from T3D-infected primary cardiac myocyte
and primary cardiac ﬁbroblast cultures and was used as template for
oligo-dT-primed cDNA synthesis and qRT-PCR. Finally, qRT-PCR
products for IFN-α2, -α4, and α5 were sequenced using pyrosequen-
cing technology, conﬁrming the subtype speciﬁcity for these primer
pairs (examples in Fig. 1).
Basal and reovirus T3D-induced expression of IFN-α is subtype and cell
type speciﬁc in cardiac cells
In order to determine whether T3D infection induces IFN-α and
whether induction is subtype speciﬁc in cardiac cells, primary cardiacPrimer sequence (5′→3′) Product size
TAATTCCTACGTCTTTTCTTT 81
TATGCCTGATCCCTGAACAGT
TGAAGGACAGGAAGGACTTTG 167
GAATGAGTCTAGGAGGGTTGT
TTGAAGGTCCTGGCACAG 160
GAGGTTCAAGGTCTGCTGA
GCAGAAGTCTGGAGAGCCCTC 122
TGAGATGCAGTGTTCTGGTCC
CTCAAAGCCTGTGTGATGCAA 123
GTGTTTCTTCTCTCTCAGGTA
CCCTGAAGATCCAGAAAGAGA 118
GTATCTAGGAGGGTTGCATCC
CATCTGCTGCTTGGGATGGAT 125
TTCCTGGGTCAGAGGAGGTTC
AGGTGGGGGTGCAGGAACTTT 97
TTCTTCTCTCTCAGGAACACA
TCATAACCTCAGGAACAAGAA 81
TCCACCTTCTCCAAGGGGAAT
CTCATTACCTTCAGTGTGAAC 93
AGATACAAAAGTGGCTATACA
CCTGACCCAGGAAGACTCCCA 114
ACTTCTGCTCTGACCACCTCC
GAGAAGAGATCAAGAAAAATG 111
TCCCAGGACTGGCTTATGAGG
CAGCAGGTGGGGGTGCAGGAG 102
TTTCTTCTCTCTCAGGTACAC
GGTGGTCAGAGCAGAAGTCCA 112
GTTCAGAAGAGTCCTCTCCAC
TTCTGCAATGACCTCAACACT 119
AAGTATTTCCTCACAGCCAGC
r pairs. Single peaks in a standard melt–curve analysis indicated ampliﬁcation of a single
4.
Fig. 1. Pyrosequencing conﬁrmation of IFN-α products. The indicated IFN-α sequences (accession numbers provided in Table 1) were aligned by ClustalW2. Regions recognized by
pyrosequencing primers for IFN-α4 (A) and -α5 (B) are indicated. Bold italic lower case indicates primer sequences, bold uppercase (unshaded) indicates the region sequenced for
each product, and bold shaded uppercase indicates IFN-α subtype-speciﬁc sequence polymorphisms. Representative spectra using primers speciﬁc for IFN-α4 (C) and -α5 (D) are
provided. The nucleotides provided during successive pyrosequencing cycles are indicated on the X axis, and sequence is interpreted from the height of the peak. For example, in
panel C, following the E (enzyme) and S (substrate), the sequence is C (single peak), AA (double peak, speciﬁc for IFN-α4), no T (indicating no IFN-α2, -α5, -α9, -α11, or -α12), no G,
no A, CC (double peak), no T, no C, no G, AA (double peak), and C (indicating no IFN-α1, -α6T, -α7, -α8/6, -α12, or α-14).
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infected or infected with T3D, and RNA was harvested at 8 h post-
infection for qRT-PCR. As reported previously (Sherry et al., 1998;
Stewart et al., 2005; Zurney et al., 2007), T3D induced IFN-β in both
cell types. Results indicated that ﬁve of the 13 IFN-α subtypes were
induced in both cell types: IFN-α1, -α2, -α4, -α5, and -α8/6. Other
IFN-α subtypes were either undetectable or the induction was less
than 2-fold relative to mock-infected cultures. Therefore, additional
experiments focused on these ﬁve IFN-α subtypes only.
IFN-β and IFN-α4 were both expressed at higher basal levels in
cardiac myocytes than in cardiac ﬁbroblasts (Fig. 2A), suggesting that
the two genes may be regulated by a common cell-type-speciﬁc
mechanism. In contrast, IFN-α1, -α2, -α5, and -α8/6 were expressed
at similar basal levels in the two cardiac cell types (Fig. 2A). Finally,
IFN-α8/6was expressed at signiﬁcantly higher basal levels than IFN-β
or any other IFN-α subtype (P values b0.05 in all cases, except for IFN-
α4 in myocytes), suggesting unique regulation of its basal expression
by a mechanism common to both cardiac cell types.
At 8 h post-infection with T3D, as previously seen for IFN-β
(Zurney et al., 2007), all ﬁve IFN-α subtypes were induced to higher
expression in cardiac myocytes than in cardiac ﬁbroblasts (Fig. 2B). In
both cell types, IFN-β expression was approximately 2- to 3-fold
higher than IFN-α4 expression (ﬁbroblasts and myocytes, respective-
ly), and all other IFN-α subtypes were expressed at signiﬁcantly lowerlevels. However, IFN-α2 was among the most highly expressed IFN-α
subtypes in cardiacmyocytes but among the least expressed in cardiac
ﬁbroblasts.
To compare relative expression of the different IFN-α subtypes,
expression for each IFN-α subtype was calculated as a percentage of
IFN-β expression (Fig. 2C). Notably, while IFN-α1, IFN-α2, IFN-α5,
and IFN-α8/6 were expressed at 6–26% the level of IFN-β in cardiac
ﬁbroblasts, these same IFN-α subtypes were expressed at only 0.5–2%
the level of IFN-β in cardiac myocytes, a 10-fold difference between
cell types. Together, the data suggest that the type I IFNs induced by
viral infection are predominantly IFN-β and IFN-α4 in cardiac
myocytes but IFN-β and multiple IFN-α subtypes in cardiac
ﬁbroblasts.
To identify possible differences in the cell response to viral
infection, T3D induction of IFN was calculated as fold induction
relative to basal expression (Fig. 2D). As previously seen for IFN-β
(Zurney et al., 2007), T3D infection resulted in a signiﬁcantly greater
fold induction for each of the ﬁve IFN-α subtypes in cardiac myocytes
than in cardiac ﬁbroblasts. Moreover, while the range of induction in
cardiac myocytes for IFN-β, -α2, -α4, and -α5 spanned a N16-fold
difference (448-fold for IFN-α5 to 7467-fold for IFN-β), the range in
cardiac ﬁbroblasts spanned only a b3-fold difference (259-fold for
IFN-α5 to 712-fold for IFN-β). Nonetheless, the relative order was
very similar between the two cell types. Together, the data suggest
Fig. 2. Basal and reovirus T3D-induced expression of IFN-α is subtype and cell type speciﬁc in cardiac cells. Primary cardiac cell cultures were mock infected or infected with reovirus
T3D at an MOI of 10 pfu/cell. Total cell RNA was extracted from replicate culture wells at 8 h post-infection for qRT-PCR. Copy number for each gene of interest was normalized to
GAPDH and then further normalized to compensate for differences in GAPDH expression between cardiac myocytes and cardiac ﬁbroblasts (see Materials and methods). Results are
the mean of replicate samples±SEM and are representative of two (A) or three (B) independent experiments. (A) Basal expression in mock-infected cultures (note Y axis indicates
multiplied by 107). (B) T3D-induced expression (note Y axis indicates multiplied by 105). (C) T3D-induced expression for each IFN-α subtype relative to IFN-β in that cell type
(calculated from panel B as e.g. [normalized copies IFN-α1/normalized copies IFN-β]×100). (D) Fold induction, calculated from data in panels (A) and (B) (as e.g. [normalized copies
T3D-induced IFN-α1]/[normalized basal copies IFN-α1]). Inset presents a subset of the same data on an ampliﬁed scale.
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more quantitative than qualitative.
To investigate IFN-α induction over time, RNAwas harvested from
primary cardiac cell cultures at 4–24 h post-infection with T3D. The
four most abundantly induced IFN-α subtypes were quantiﬁed by
qRT-PCR (Fig. 3). The trends in relative expression levels for the
different IFN-α subtypes were very similar to the single 8 h time
points in Fig. 2. To investigate secreted IFN-α, supernatants were
harvested between 4 and 24 h post-infection of primary cardiac cell
cultures, and total IFN-α was quantiﬁed by ELISA (Fig. 4). T3D
induction of secreted IFN-α was signiﬁcant by 8 h post-infection for
cardiac myocytes (Pb0.001) but only at 24 h post-infection for cardiac
ﬁbroblasts (P=0.002) and was signiﬁcantly higher for cardiac
myocytes than cardiac ﬁbroblasts at 12 and 24 h post-infection
(P=0.05 and 0.002, respectively). Therefore, reovirus T3D induction
of secreted IFN-α, like IFN-α mRNA, is cell type speciﬁc.
Reovirus T3D induction of IFN is both direct and indirect and is subtype
and cell type speciﬁc in cardiac cells
In some cell types, viral infection induces initial synthesis and
secretion of IFN-β and IFN-α4, which then signal through the IFN-
α/β receptor to induce IRF7 for subsequent further induction of
IFN-β, IFN-α4, and other IFN-α subtypes (Honda et al., 2005; Marie
et al., 1998; Sato et al., 1998). To determine whether reovirus T3Dinduction of IFN-α is direct or is mediated by IFN-α/β, primary
cardiac cell cultures were generated from IFN-α/β-receptor-null
mice, and reovirus T3D induction of IFN was quantiﬁed by qRT-PCR.
Basal expression of IFN mRNA was either undetectable or very low
in IFN-α/β-receptor-null cells (data not shown) relative to wild-
type cells (Fig. 2A), and suggested a ≥5-fold decrease in IFN-β, IFN-
α4, and IFN-α8/6 in cardiac myocytes and a ≥5-fold decrease in
IFN-α8/6 in cardiac ﬁbroblasts (data not shown). Basal expression
of other IFN mRNA types was too low in wild-type cells (Fig. 2A) to
extrapolate reduction in IFN-α/β-receptor-null cells. T3D induced
IFN-β and IFN-α4 signiﬁcantly in IFN-α/β-receptor null cultures,
but expression was dramatically decreased relative to wild type
cardiac cell cultures (Fig. 5). Interestingly, while the reduction in
expression was greater in cardiac myocytes than cardiac ﬁbroblasts
for both IFN-β and IFN-α4, the reduction was most dramatic for
T3D-induced IFN-α4 expression in cardiac myocytes (Fig. 5B),
resulting in an inversion where cardiac ﬁbroblasts expressed more
IFN-α4 than cardiac myocytes. Reduction in expression for other
IFN-α subtypes ranged from 10- to 100-fold (data not shown) or
was not possible to extrapolate given the low expression in wild-
type cultures (Fig. 2B). Together, the data suggest that IFN-mediated
ampliﬁcation is more critical for T3D-induced IFN-α expression, in
particular for IFN-α4, than for IFN-β expression in cardiac myocytes.
In contrast, T3D-induced type I IFN in cardiac ﬁbroblasts is less
dependent on IFN-mediated ampliﬁcation.
Fig. 3. Peak time of IFN-α induction by reovirus T3D is cell type and subtype speciﬁc.
Primary cardiac cell cultures were infected as for Fig. 2. Total cell RNA was extracted
from replicate culture wells at the indicated time post-infection for qRT-PCR and
analyzed as for Fig. 2. Results are the mean of replicate samples±SEM and are
representative of three independent experiments. (A) Cardiac myocyte cultures. (B)
Cardiac ﬁbroblast cultures.
Fig. 4. Reovirus T3D induction of secreted IFN-α is cell type speciﬁc. Primary cardiac cell
cultures were infected as for Fig. 2, and supernatants from duplicate wells were
harvested at 4, 8, 12, and 24 h post-infection for quantiﬁcation of secreted total IFN-α
by ELISA. “Mock” is an average of samples harvested at 4 and 24 h post-infection. Data
are expressed as mean±SD.
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and -β in cardiac cells
To determine whether IFN-α or IFN-β induces type I IFN in cardiac
cells in the absence of viral infection, primary cardiac cell cultures
were treated with murine IFN-β or individual IFN-α subtypes at
1000 U/ml. Total RNA was harvested at 2 and 5 h post-treatment, and
IFN expression was assessed by qRT-PCR (duplicate experiments, data
not shown). Neither IFN-β nor any of the IFN-α subtypes tested
induced type I IFN in cardiac cells in the absence of viral infection.
IFN induction of ISG expression is subtype and cell type speciﬁc
To determine whether individual IFN-α subtypes can signal in
cardiac cells, IFN-α subtype induction of two ISGs was assessed by
qRT-PCR (Fig. 6). The ISG IRF-7 was chosen for its importance in the
positive feedback loop for IFN induction (Honda et al., 2005; Marie et
al., 1998; Sato et al., 1998), and the ISG 56 was chosen as onerepresentative antiviral ISG. IFN-α induction of ISGs was greater in
cardiac ﬁbroblasts than in cardiac myocytes, consistent with previous
results for IFN-β in these cell types (Stewart et al., 2005; Zurney et al.,
2007). At 8 h post-treatment, the trend for IRF7 expression was
similar in the two cells types, with the greatest induction by IFN-β and
IFN-α4 and the lowest induction by IFN-α2. A similar trend was seen
for ISG 56 expression, except that expression decreased by 8 h post-
treatment in cardiac myocytes. Thus, cardiac myocytes and cardiac
ﬁbroblasts are differentially sensitive to IFN-α treatment as previ-
ously seen for IFN-β (Zurney et al., 2007), and signaling in cardiac cells
is IFN-α subtype speciﬁc.
Reovirus T3D sensitivity to IFN-α is subtype speciﬁc in cardiac cells
To determine whether individual IFN-α subtypes can provide
antiviral protection to cardiac cells, primary cardiac cell cultures were
pre-treated with IFN-α subtypes and then challenged with reovirus
T3D (Fig. 7). In both cardiac myocytes and cardiac ﬁbroblasts, each
IFN-α subtype tested decreased viral replication at 1000 U/ml, with
decreased effects at 100 U/ml. And in both cell types, IFN-β provided
the greatest antiviral protection, while IFN-α1 and IFN-α2 provided
the least protection.
Discussion
IFN-α and IFN-β bind a shared receptor to induce expression of an
overlapping set of antiviral genes (Jaks et al., 2007), and both
cytokines have been used successfully in the treatment of human viral
myocarditis (Daliento et al., 2003; Kuhl et al., 2003, 2006; Miric et al.,
1996; Stille-Siegener et al., 1995) . However, the only investigation
measuring expression of different IFN-α subtypes in the heart during
murine viral myocarditis used CVB3 (Baig and Fish, 2008), which
induces both direct and immune-mediated damage (Huber, 2008;
Whitton, 2002). Therefore, the IFN-α in that study likely reﬂected
contributions from both cardiac and inﬂammatory cells. Similarly,
there has been only one investigation comparing the efﬁcacy of
different IFN-α subtypes in protection against murine viral myocar-
ditis (Bartlett et al., 2004; Cull et al., 2002), and that study also used a
virus that mediates cardiac damage primarily through immune-
mediated rather than direct mechanisms (MCMV; Lenzo et al., 2003).
There have been no studies comparing cardiac expression of the
different IFN-α subtypes using a virus that mediates direct damage to
the heart or using cardiac cells to assess expression of different IFN-α
subtypes and their relative importance in the cardiac protective
Fig. 5. The role of IFN-mediated ampliﬁcation in T3D induction of type I IFN is cell type
speciﬁc. Primary cardiac cell cultures were generated from IFN-α/β-receptor-null and
wild-type mice. Cultures were infected and RNA was harvested at 8 h post-infection
and analyzed as for Fig. 2. (A) Results are the mean of duplicate samples from each of
two experiments±SEM. (B) Results in panel A from wild-type cells were divided by
those from IFN-α/β-receptor-null cells.
Fig. 6. IFN-α induction of ISG mRNA is subtype and cell type speciﬁc. Primary cardiac
cell cultures were treated with media or 1000 U/ml of the indicated IFN type, and RNA
was harvested at the indicated time post-treatment for qRT-PCR analysis. Copy number
for each sample was normalized to GAPDH expression and then divided by copy
number in replicate media-treated cultures harvested at the same time to calculate fold
induction. Results are expressed as the mean of duplicate samples±SD, and are
representative of three independent experiments. (A) IRF7 expression. (B) ISG 56
expression.
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cells, that it is both subtype and cell type speciﬁc, and that it is likely
important in the antiviral cardiac response.
Investigations comparing expression for the different IFN-α
subtypes have been hindered by the N80% DNA homology between
genes (Hardy et al., 2004; van Pesch et al., 2004). One recent study
used ﬂuorescein-labeled probes in a heteroduplex analysis of PCR
products generated from consensus primers (Demoulins et al., 2009).Several other recent studies used IFN-α subtype-speciﬁc primers, one
for Taqman-based qRT-PCR (Loseke et al., 2003) and two for
Sybergreen-based qRT-PCR (Baig and Fish, 2008; Izaguirre et al.,
2003). Here, we took advantage of the extreme speciﬁcity of the 3′
terminal nucleotide for primer extension to design primers that could
be used for Sybergreen-based qRT-PCR, a much less expensive option
than Taqman-based qRT-PCR.We also used pyrosequencing in a novel
approach to validate the speciﬁcity of qRT-PCR products without the
need for subcloning. Results provide not only insights into differential
IFN-α subtype expression in cardiac cells but also a method for
quantitatively comparing and validating expression from closely
related genes.
IFN-α is expressed at detectable levels in some tissues even
without stimulation (Brandt et al., 1994; Marie et al., 1998; Tovey et
al., 1987; Zoumbos et al., 1985). High basal expression of IFN-α can
directly protect cells from virus infection (Bautista et al., 2005) and
can determine high basal expression of IRF7 and thereby increase viral
induction of IFN through a positive ampliﬁcation loop (Hata et al.,
2001). High basal IFN-α can also stimulate maturation and activation
of dendritic cells (Montoya et al., 2002) and can augment cell
responses to IFN-γ (Takaoka et al., 2000) and IL-6 (Mitani et al., 2001).
Here, we found that basal expression of IFN-α was both subtype and
cell type speciﬁc in cardiac cells. We previously demonstrated that
high basal type I IFN expression in cardiac myocytes stimulates high
Fig. 7. Reovirus T3D sensitivity to IFN-α is subtype speciﬁc in cardiac cells. Primary
cardiac myocyte cultures and primary cardiac ﬁbroblast cultures were treated with IFN-
α1, -α2, -α4, -α5, or -β at 100 or 1000 U/ml, incubated for 24 h, challenged with
reovirus T3D at anMOI of 10 pfu/cell, and then incubated an additional 20 h. Viral titers
were determined by plaque assay (Fig. 8A, expressed as mean±SD from triplicate
samples), and fold inhibition by IFN treatment was determined (Fig. 8B, expressed as
IFN-treated relative to mock-treated samples). Results are representative of two
independent experiments. In each cell type at 1000 U/ml, relative inhibition of viral
titers were IFN-βNα5=α4Nα2=α1 (Pb0.05 by ANOVA).
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arming in cardiac myocytes from both protective ISGs and latent IRF7
expression (Zurney et al., 2007). Results here indicate that this type I
IFN could be comprised of both IFN-β and IFN-α4 but not IFN-α1, -α2,
-α5, or -α8/6 since they were expressed at basal levels that were
equivalent in the two cell types (Fig. 2). In addition, results here
demonstrate that IRF7 is not active in cardiac myocytes in the absence
of viral infection, consistent with results seen in other cell types. That
is, high basal IRF7 expression in cardiac myocytes did not result in
higher basal expression of downstream IFN-α subtypes in that cell
type relative to cardiac ﬁbroblasts (Fig. 2). The mechanism underlying
high basal expression of IFN-β and IFN-α4 in cardiac myocytes
remains unclear.
Type I IFN expression is enhanced by an IRF7-mediated positive
ampliﬁcation loop (Honda et al., 2005; Marie et al., 1998; Sato et al.,
1998) and cell-type-speciﬁc differences in IRF7 expression can
therefore determine viral induction of IFN-α. Indeed, differences in
virus-induced expression for two different human IFN-α subtypes
reﬂects differences in organization of IRF elements in the promoters of
their genes (Civas et al., 2006; Genin et al., 2009). Constitutive IRF7
levels correlatewith levels of both IFN-α4 and IFN-non-α4 induced by
inﬂuenza virus in several cell types, and high constitutive IRF7
overcomes the requirement for the positive ampliﬁcation loop forexpression of both IFN-α classes (Prakash et al., 2005).West Nile virus
induction of IFN-α is reduced in multiple primary cell types deﬁcient
in IRF7, but interestingly, IFN-β is not (Dafﬁs et al., 2008). However, no
previous studies have addressed the impact of IRF7 expression levels
on viral induction of different IFN-α subtypes. Previously, we found
that reovirus T3D induces greater IRF7 in cardiac ﬁbroblasts than in
cardiac myocytes (Stewart et al., 2005), consistent with the greater
responsiveness of the former than the latter to IFN signaling and
reﬂecting differences in basal expression of the JAK–Stat pathway
(Zurney et al., 2007). Here, we found that while IFN-β and IFN-α4
comprised the majority of type I IFN induced by reovirus in both
cardiac cell types, the relative contribution from the other subtypes
differed dramatically, providing only 4% of the total type I IFN in
cardiac myocytes but 27% of the total in cardiac ﬁbroblasts (Fig. 2B).
Moreover, reovirus induced IFN-non-α4 subtypes to a combined level
of only 6% that of IFN-β in cardiac myocytes, but 56% the level of IFN-β
in cardiac ﬁbroblasts (Fig. 2C). These data would suggest that cell-
type-speciﬁc differences in virus-induced IRF7 levels (Stewart et al.,
2005) correlate with differences in viral induction of IFN-α subtypes
downstream of IRF7. However, in contrast, viral induction of IFN-α4
and IFN-β in cells lacking IFN-α/β signaling was reduced much more
in cardiac myocytes than in cardiac ﬁbroblasts (Fig. 5). This may
reﬂect the fact that basal IRF7 expression is much greater in cardiac
myocytes than in cardiac ﬁbroblasts, and that this basal expression is
dependent on IFN-α/β signaling (Stewart et al., 2005). If basal IRF7
expression contributed to viral induction of IFN-β and IFN-α4, then
viral induction of these two IFN types would be more dependent on
IFN-α/β signaling in cardiac myocytes than in cardiac ﬁbroblasts, as
was seen here (Fig. 5). Finally, IFN-α/β signaling was more critical for
viral induction of IFN-α4 than IFN-β in cardiac myocytes (Fig. 5).
Induction of these two IFN types is generally coincident, as they are
both induced directly by virus and also through the ampliﬁcation loop
(Honda et al., 2005; Marie et al., 1998; Sato et al., 1998). Differential
expression of IFN-β and IFN-α subtypes in human cells is determined,
at least in part, by different promoter interactions with IRF3 and IRF7
(Genin et al., 2009). Indeed, IRF3 can repress IRF7 induction of some
human IFN-α subtypes (Genin et al., 2009). If viral induction of mouse
IFN-α4 was more dependent than IFN-β on IRF7, then, as was seen
here (Fig. 5), IFN-α4 induction would be more dependent than IFN-β
on IFN-α/β signaling (for both basal IRF7 expression (Stewart et al.,
2005) and IFN-induced IRF7 expression). These data would suggest
that, as for West Nile virus comparisons between total IFN-α and IFN-
β (Dafﬁs et al., 2008), the role of IRF7 in reovirus induction of type I
IFN varies between IFN types and is cell type speciﬁc.
IFN-α subtypes differ in their antiviral activity both in vitro and in
vivo. When COS cells were transfected with constructs expressing
murine IFN-α1, -α2, -α4, and -α6, and then supernatants were tested
for protection of L929 and CHO cells against challenge with vesicular
stomatitis virus, IFN-α4 was most effective (Van Heuvel et al., 1986).
But when puriﬁed recombinant IFN-α1 and -α4 were tested for
protection of L929 and J2E cells against encephalomyocarditis virus
challenge, the two subtypes were equivalent (Swaminathan et al.,
1992). IFN-α1, -α4, or -α9 transgenes introduced into regenerating
muscles of mice each reduced MCMV replication, with IFN-α1
providing the most protection (Yeow et al., 1998). When IFN
transgenes were applied vaginally to mice before challenge with
HSV-2, IFN-α1, -α5, and -β were protective while IFN-α4, -α6, and
-α9 were not (Austin et al., 2006). Finally, when mice were injected
with constructs expressing IFN-α subtypes and challenged with
inﬂuenza virus, IFN-α5 and -α6 were most and IFN-α1 least
protective (James et al., 2007). Together, the data suggest that the
antiviral activity of murine IFN-α subtypes may be both virus and
tissue speciﬁc. Similar differences in antiviral activity have been seen
for human IFN-α subtypes (Foster et al., 1996; Koyama et al., 2006;
Larrea et al., 2004; Schanen et al., 2006). Interestingly, IFN-α subtypes
may differ in antiviral activity but not anti-proliferative function, or
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found that the relative antiviral activity for type I IFNs was the same
for cardiac myocytes and cardiac ﬁbroblasts: IFN-β provided the
greatest protection, IFN-α4 and -α5 were intermediate, and IFN-α1
and -α2 provided the least protection (Fig. 7). These relative antiviral
effects parallel relative IFN subtype-speciﬁc induction of ISGs (Fig.6;
8 h post-treatment), perhaps reﬂecting differences in afﬁnity for the
IFN-α/β-receptor (Jaks et al., 2007). Finally, IFN-β, -α4, and -α5 were
expressed at higher levels than IFN-α1 and -α2 in cardiac ﬁbroblasts
after reovirus infection (Fig. 2B), potentially contributing even further
to their protective functions in the heart.
Viral induction of IFN (Fig. 2), IFN induction of ISGs (Fig. 6),
and IFN antiviral activity (Fig. 7) were always greater for IFN-β
than for any IFN-α subtype. This is consistent with previous
evidence for greater activation of the JAK–Stat pathway (Grumbach
et al., 1999) and greater antiviral activity of IFN-β than IFN-α
(pooled preparations) against CVB3 (Heim and Weiss, 2004) in
human cardiac ﬁbroblasts. Indeed, IFN-β provides protection
against inﬂuenza virus in mice that cannot be provided by IFN-α
alone (Koerner et al., 2007). Nonetheless, while the combined
expression of IFN-α subtypes was only 26% of the total IFN in
infected cardiac myocytes, it was 52% of the total in infected
cardiac ﬁbroblasts (Fig. 2B). Given that cardiac ﬁbroblasts are more
responsive than cardiac myocytes to both IFN-α (Fig. 6) and IFN-β
(Stewart et al., 2005; Zurney et al., 2007), this contribution of IFN-
α could be particularly important in cardiac ﬁbroblasts. Finally,
although combined antiviral effects cannot be extrapolated from
the data, IFN-α4 and -α5 each expressed 15% of the antiviral
activity of IFN-β in cardiac myocytes, and 16 to 23% the activity in
cardiac ﬁbroblasts (Fig. 7B). Together, the data indicate that IFN-α
subtypes are likely to play an important role in protecting the
heart from viral infection.
Materials and methods
Mice
Timed-pregnant Cr:NIH(S) mice were purchased from the Nation-
al Cancer Institute. IFN-α/β-receptor-null mice (Muller et al., 1994)
were maintained as breeding colonies to generate neonates and
fetuses for generation of primary cell cultures. Mouse facilities were
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care, and all procedures were approved by the
North Carolina State University institutional animal care and use
committee.
Primary cell cultures
Primary cardiac myocyte cultures and primary cardiac ﬁbroblast
cultures were generated from 1- or 2-day-old neonatal or term fetal
mice according to the method described previously (Baty and Sherry,
1993). Brieﬂy, the apical two-thirds of the hearts from euthanized
neonates or fetuses were removed and trypsinized. Cells were
suspended in Dulbecco's modiﬁed Eagle's medium (DMEM; Gibco
BRL, Gaithersburg, MD) supplemented with 7% fetal calf serum and
10 μg of gentamicin (Sigma Co.) per ml (cDMEM). Cells were plated in
6-well clusters and incubated for 2 h for separation by differential
adhesion. Cardiac myocytes were harvested from the supernatant and
the adherent cardiac ﬁbroblasts were harvested by trypsinization.
Following centrifugation, cardiac myocytes were suspended in
cDMEM plus 0.06% thymidine (Sigma Co., St. Louis, MO), cardiac
ﬁbroblasts were suspended in cDMEM, and both cultures were
incubated in a 37 °C, 5% CO2 incubator. Cells were never passaged
before use. By immunoﬂuorescent staining, myocyte cultures
contained b5% ﬁbroblasts while ﬁbroblast cultures contained b1%
myocytes (Zurney et al., 2007).Viruses and cell lines
Reovirus type 3Dearing (T3D; Schiff et al., 2007)was plaquepuriﬁed
and ampliﬁed in mouse L929 cells, which were maintained in a sus-
pension system in sMEM (SAFC Biosciences, Denver, PA) supplemented
with 5% fetal calf serum (Atlanta Biologicals, Atalanta, GA) and 2 mM L-
glutamine (Mediatech Inc., Herndon, VA). Virus was puriﬁed by CsCl
gradient centrifugation (Smith et al., 1969) for use in all experiments.
Infection for T3D induction of IFN-α
Cardiac myocytes from Cr:NIH(S) mice were plated at 1×106
cells/well and cardiac ﬁbroblasts were plated at 5×105 cells/well in
2 ml media in 24-well clusters. Cardiac ﬁbroblasts were assumed to
double after 2 days of incubation. All cultures were washed twice, and
duplicate wells were infected at an MOI of 10 pfu/cell 2 days post-
plating. Virus suspended in 700 μl of cDMEM with or without
thymidine was added to each well, and cells were incubated in 37 °C,
5% CO2 incubator for 1 h. Then an additional 1000 μl cDMEM with or
without thymidine was added to each well. Mock-infected cells were
treated identically except the inocula lacked virus.
Cardiac myocytes from IFN-α/β-receptor-null mice were plated at
5×105 cells/well and cardiac ﬁbroblasts were plated at 2.5×105
cells/well in 1 ml media in 48-well clusters. Infections were as above,
except that virus inoculum was 350 μl/well, and an additional 500 μl
media were added after the 1 h incubation.
Infection for T3D sensitivity to IFN-α
Cardiac myocytes from Cr:NIH(S) mice were plated at 1.5×105
cells/well and cardiac ﬁbroblasts were plated at 7.5×104 cells/well in
300-μl media in 96-well clusters. Cardiac ﬁbroblasts were assumed to
double after 2 days of incubation. Twenty-four hours post-plating,
cells were washed once, and overlying medium was replaced with
300 μl of IFN-β, -α1, -α2, -α4, or -α5 at 100 or 1000 U/ml in cDMEM
with or without thymidine in triplicate wells (IFN-β: cat # 12400-1;
IFN-α subtypes: a gift of puriﬁed recombinant preparations quantiﬁed
in a standard IFN assay measuring protection of L929 cells against
encephalomyocarditis virus challenge; both from PBL Biomedical
Laboratories, Piscataway, NJ). After an additional overnight incuba-
tion, cells were washed twice, infected with T3D at an MOI of 10 pfu/
cell in 100 μl inoculum, and incubated for 1 h in a 37 °C, 5% CO2
incubator. Cells were washed once, and the appropriate IFN at 100 or
1000 U/ml in 250 μl cDMEMwith or without thymidine was added to
each well. Control cells lacked IFN treatment but were infected with
T3D as above. After 20 h incubation, cultures were stored at −80 °C,
frozen and thawed an additional two times, and supplemented to a
ﬁnal 0.5% Nonidet P-40 (Sigma). Serial dilutions were used to infect
L929 cells in a standard plaque assay (Sherry et al., 1996).
Harvesting cultures for RNA and ELISA
Supernatants and RNA were harvested at indicated times post-
infection or post-treatment with IFN (from PBL as above). Super-
natants were stored at –35 °C, and remaining cells were lysed directly
on the plate using cell lysis buffer from an RNeasy Kit (Qiagen, Inc.,
Valencia, CA) supplemented with 1% β-mercaptoethanol. Cell lysates
were homogenized using Qiashredders (Qiagen, Inc.), and total RNA
was isolated using the RNeasy Kit according to the manufacturer's
instructions. Genomic DNA was removed using RNase-free DNase I
(Qiagen, Inc.). The isolated RNA was stored at −80 °C.
Reverse transcription (RT) and quantitative (q)RT-PCR
To generate cDNA, one third of the RNA harvested from each well
in a 24-well cluster or two thirds from a 48-well cluster was used as
67L. Li, B. Sherry / Virology 396 (2010) 59–68template in a 100-μl reaction containing 5 μM oligo(dT) (Invitrogen
Corp., Carlsbad, CA), 1× Taq buffer (Promega corp., Madison, WI),
7.5 mMMgCl2 (Promega corp.), 1 mM dithiothreitol (Promega corp.),
1mMeach dNTP (Roche, Indianapolis, IN), 0.67 U/μl RNasin (Promega
Corp., Madison, WI), and 0.20 U/μl of AMV reverse transcriptase
(Promega Corp.).
Gene expression was quantiﬁed using a Sybergreen system on an
iCycler iQ ﬂuorescence thermocycler (Bio-Rad Laboratories, Hercules,
CA). Each 25-μl reaction contained 5% of the RT product, 1× Quantitech
master mix (Qiagen, Inc.), 10 nM ﬂuorescein (Invitrogen Corp.,
Carlsbad, CA), and 0.3 μM each of the forward and reverse primers
(IFN-β forward: 5′-GGAGATGACGGAGAAGATGC-3′ and reverse: 5′-
CCCAGTGCTGGAGAAATTGT; GAPDH forward: 5′-GGGTGTGAACCAC-
GAGAAAT-3′ and reverse: 5′-CCTTCCACAATGCCAAAGTT-3′; IFN-α as
indicated in Table 1). iCyclerTM iQ Optional System Software, version
3.0 (Bio-Rad Laboratories), was used to analyze the data. Standard
curves (generated from serial dilutions of known concentrations of
puriﬁed PCR products) were used to quantify copy number. Individual
cDNA standards for each IFN-α subtype were puriﬁed PCR products,
using primers to generate products that contain the primers indicated
in Table 1, as follows: IFN-α1 (334 bp) forward: 5′-GGAACAAGA-
GAGCCTTGACA-3′ and reverse: 5′-CTCACAGCCAGCAGGGCAT-3′;
IFN-α2 (626 bp) forward: 5′-TCTGTGCTTTCCTCGTGATG-3′ and
reverse: 5′-GATGCAGTTTCTAGTCCAGG-3′; IFN-α4 (295 bp) forward:
5′-CTGCTGGCTGTGAGGACATA-3′ and reverse: 5′-TTGCTCAA-
GATTGCTGAAACA-3′; IFN-α5 (603 bp) forward: 5′-AGAGCCT-
TAACCCTCCTGGT-3′ and reverse: 5′-CGCTCAAGATTGCTGAAACA-3';
IFN-α8/6 (240 bp) forward: 5′-CCTGATGGTTTTGGTGGTGT-3′ and
reverse: 5′-ATCTGCTGGGTCAGCTCAG-3′. Gene-of-interest expression
was normalized to GAPDH gene expression and then further normal-
ized to account for differences in GAPDH expression in myocytes and
ﬁbroblasts. For example, normalized copies IFN-β inmyocyte sample=
[(copies IFN-β in myocyte sample)/(copies GAPDH in myocyte
sample)]×(average copies GAPDH in all myocyte samples)/(average
copies GAPDH in all ﬁbroblast samples). Normalized copies IFN-β in
ﬁbroblasts=(copies IFN-β in ﬁbroblast sample)/(copies GAPDH in
ﬁbroblast sample) with no further normalization for differences
between cell types since that was already accounted for in myocytes.
Pyrosequencing to conﬁrm qRT-PCR products
qRT-PCR products were generated as above, except that one primer
of the primer pair was biotinylated at its 5′ terminus (Invitrogen). A 50%
slurry of Streptavidin Sepharose™ High Performance beads (GE
Heathcare, Piscataway, NJ) was suspended in Binding buffer (10 mM
Tris–HCl, pH 7.6, 2 M NaCl, 1 mM EDTA, 0.1% Tween 20; Biotage,
Charlottesville, VA) for a ﬁnal 5% slurry. Primers for pyrosequencing
were suspended in annealing buffer (20 mM Tris–acetate pH 7.6, 2 mM
Mg-acetate; Biotage) at a ﬁnal concentration of 0.4 μM. Ten microliters
(40%)of qRT-PCRproductswasmixedwith the streptavidin beads in 96-
well clusters (Corning, NY) and then transferred to PSQ 96 Sample Prep
Thermoplates (Low; Biotage) for Pyrosequencing, using Pyro Gold
Reagents (Biotage) according to the manufacturer's instructions.
Primers for pyrosequencing were GAPDH (5′-GGTCTACATGTTCCAG-
TATG-3′); IFN-β (5′-CGGAGAAGATGCAGAAGAGT-3′); IFN-α2 (5′- ATT-
CCCCCTGGAGAAGGTG-3′); IFN-α4 (5′-CTGGAGAGCCCTCTCTTCCT-3′);
and IFN-α5 (5′-AGCCTGTGTGATGCAACAGG-3′).
ELISA
Expression of IFN-α protein was determined using a mouse IFN-α
ELISA kit (PBL Biomedical Laboratories) according to the manufac-
turer's instructions. Brieﬂy, 100 μl supernatant from each sample (24-
well clusters) was measured. A standard curve was constructed
ranging from 0 to 500 pg/ml, using serial dilutions of a mouse IFN-α
standard provided with the kit. Absorbance was detected at 450 nmon a Tecan Sunrise Microplate Reader (Tecan Systems Inc., San Jose,
CA).
Statistical analysis
A Student's two-sample t-test (pooled variance) was applied for
all cases except for Fig. 7, where ANOVA (Tukey's test) was applied
(Systat 9.0). Results were considered signiﬁcant at Pb0.05.
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